Again, we can only hope he is wrong...
The following predictions are distilled from an in-depth analysis of how the precipitated evolutionary dynamics of SARS-CoV-2 (SC-2) in highly vaccinated populations enable the virus to bypass the cell-based innate immune system (CBIIS) and exhaust the adaptive immune capacity in vaccinees while providing ‘power training’ to the CBIIS of the unvaccinated. Understanding the immunological consequences of this complex phenomenon provides new insights as to why sidelining of the CBIIS dramatically enhances the susceptibility of vaccinees to re-infection with more infectious variants.
Furthermore, it explains how these individuals are now forming an asymptomatic reservoir of ‘more virulent’ SC-2 variants (BA.4 and BA.5), and to some extent other
glycosylated viruses causing acute self-limiting (viral) infection (ASLVI) or disease (ASLVD)
When one grasps the above-summarized dynamics it becomes crystal clear that vaccinating young children against C-19 entails trading a highly ephemeral benefit
(short-lived protection from severe C-19 disease) for an immense risk of severe disease from a multitude of other acute or chronic microbial infections or immunopathologies, the consequences of which are simply dramatic. As the forementioned ailments will primarily affect vaccinees and highly vaccinated countries, it is reasonable to assume that the unvaccinated and countries with low C-19 vaccine coverage rates will largely resist the pandemic storms as their capacity to build natural and herd immunity has not been compromised (‘Africa will win’).
The primary focus of highly vaccinated countries should now be early C-19 treatment of vaccinees and massive distribution of antivirals
that are safe and effective and can be provided in sufficient quantities at affordable cost to these individuals.
As infection-enhancing Abs in vaccinees are boosted upon each re-exposure to the more infectious circulating virus, these Abs are raising the immune pressure on viral
virulence which—for now—is still capable of preventing severe disease (although only for a limited amount of time!). However, this rising population-level immune pressure has already led to the enhanced intrinsic virulence of the virus (BA.4 and BA.5 are ‘more virulent’ variants; https://www.biorxiv....39v1.full.pdf).
The very last step the virus needs to take to fully escape the virulence-neutralizing effect of these Abs 2 Sustained activation of these T cells can also protect vaccinees against C-19 disease in the presence of high titers of infection-enhancing Abs is to select a variant (of the conserved infection enhancing site3) which no longer
sufficiently binds the infection-enhancing Abs when tethered to migrating dendritic cells (DCs; see fig. 1). Insufficient or deficient binding of these Abs to DC surface-tethered SC-2 virions will no longer allow them to prevent trans infection (leading to trans fusion, which is responsible for syncytia formation and severe disease;
https://www.voicefor...c-19-pandemic),When this occurs, protection against severe disease will
I predict that it’s only a matter of an additional few months (depending on booster shots) before the virus overcomes this final hurdle, at which point highly vaccinated populations will be devastated by massive rates of C-19 morbidity and C-19 mortality if not massively treated with antivirals. Once SC-2 has become resistant to the virulence inhibiting capacity of the infection-enhancing Abs, the latter will only contribute to precipitating and accelerating severe disease. Consequently, Ab-dependent enhancement of infection (ADEI) will now prompt Ab-dependent enhancement of disease (ADED). ADED will first manifest in vaccinees with high titers of infection enhancing Abs and vaccinated at an early stage of the vaccination program (i.e., before they had an opportunity to train their CBIIS).
Hence, elderly and vulnerable vaccinees will be affected first. Provided they had ample opportunity to train their innate immune system prior to vaccination, some vaccinees may have enough natural immune capacity left to survive—but will the hospitals still be able to treat them?
Massive suboptimal immune pressure exerted by highly C-19 vaccinated populations on the life cycle of SARS-CoV-2 drives natural selection and dominant propagation of highly infectious variants that sideline the cell-based innate immune system while subverting and eroding the adaptive immune system in ways that ignite new pandemics and epidemics with dramatic consequences. Both human and animal populations are at significant risk, particularly in countries with high C-19 vaccine coverage rates and especially within vaccinated children. These countries will severely suffer from the pandemic of ‘more virulent’ SC-2 variants once the latter have become resistant to the virulence-inhibiting activity of vaccine-induced infection-enhancing Abs.